NEDD9, an independent good prognostic factor in intermediate-risk acute myeloid leukemia patients
Por:
Pallares, V, Hoyos, M, Chillon, MC, Barragan, E, Conde, MIP, Llop, M, Cespedes, MV, Nomdedeu, JF, Brunet, S, Sanz, MA, Gonzalez-Diaz, M, Sierra, J, Casanova, I, Mangues, R
Publicada:
29 sep 2017
Resumen:
Intermediate-risk acute myeloid leukemia (IR-AML) is the largest subgroup of AML patients and is highly heterogeneous. Whereas adverse and favourable risk patients have well-established treatment protocols, IR-AML patients have not. It is, therefore, crucial to find novel factors that stratify this subgroup to implement risk-adapted strategies. The CAS (Crk-associated substrate) adaptor protein family regulates cell proliferation, survival, migration and adhesion. Despite its association with metastatic dissemination and prognosis of different solid tumors, the role of these proteins in hematological malignancies has been scarcely evaluated. Nevertheless, previous work has established an important role for the CAS family members NEDD9 or BCAR1 in the migratory and dissemination capacities of myeloid cells. On this basis, we hypothesized that NEDD9 or BCAR1 expression levels could associate with survival in IR-AML patients and become new prognostic markers. To that purpose, we assessed BCAR1 and NEDD9 gene expression in a cohort of 73 adult AML patients validating the results in an independent cohort (n = 206). We have identified NEDD9, but not BCAR1, as a new a marker for longer overall and disease-free survival, and for lower cumulative incidence of relapse. In summary, NEDD9 gene expression is an independent prognostic factor for favourable prognosis in IR-AML patients.
Filiaciones:
Pallares, V:
Hosp Santa Creu & Sant Pau, IIB St Pau, Biomed Res Inst St Pau, Barcelona, Spain
Hosp Santa Creu & Sant Pau, Dept Hematol, Barcelona, Spain
Hoyos, M:
Hosp Santa Creu & Sant Pau, IIB St Pau, Biomed Res Inst St Pau, Barcelona, Spain
Hosp Santa Creu & Sant Pau, Dept Hematol, Barcelona, Spain
Chillon, MC:
Univ Hosp Salamanca, Dept Hematol, Salamanca, Spain
Inst Invest Biomed Salamanca IBSAL, Ctr Invest Canc IBMCC, Salamanca, Spain
CIBER Oncol CIBER ONC, Madrid, Spain
Barragan, E:
Univ Hosp La Fe, Clin Lab, Valencia, Spain
Univ Hosp La Fe, Dept Hematol, Valencia, Spain
CIBER Oncol CIBER ONC, Madrid, Spain
Conde, MIP:
Univ Hosp Salamanca, Dept Hematol, Salamanca, Spain
Inst Invest Biomed Salamanca IBSAL, Ctr Invest Canc IBMCC, Salamanca, Spain
Llop, M:
Univ Hosp La Fe, Clin Lab, Valencia, Spain
Univ Hosp La Fe, Dept Hematol, Valencia, Spain
Cespedes, MV:
Hosp Santa Creu & Sant Pau, IIB St Pau, Biomed Res Inst St Pau, Barcelona, Spain
CIBER BBN, Barcelona, Spain
Nomdedeu, JF:
Hosp Santa Creu & Sant Pau, Dept Hematol, Barcelona, Spain
Brunet, S:
Hosp Santa Creu & Sant Pau, Dept Hematol, Barcelona, Spain
Sanz, MA:
Univ Hosp La Fe, Clin Lab, Valencia, Spain
Univ Hosp La Fe, Dept Hematol, Valencia, Spain
CIBER Oncol CIBER ONC, Madrid, Spain
Gonzalez-Diaz, M:
Univ Hosp Salamanca, Dept Hematol, Salamanca, Spain
Inst Invest Biomed Salamanca IBSAL, Ctr Invest Canc IBMCC, Salamanca, Spain
CIBER Oncol CIBER ONC, Madrid, Spain
Sierra, J:
Hosp Santa Creu & Sant Pau, Dept Hematol, Barcelona, Spain
Univ Autonoma Barcelona, Barcelona, Spain
Casanova, I:
Hosp Santa Creu & Sant Pau, IIB St Pau, Biomed Res Inst St Pau, Barcelona, Spain
CIBER BBN, Barcelona, Spain
Josep Carreras Leukemia Res Inst, Barcelona, Spain
Mangues, R:
Hosp Santa Creu & Sant Pau, IIB St Pau, Biomed Res Inst St Pau, Barcelona, Spain
CIBER BBN, Barcelona, Spain
Josep Carreras Leukemia Res Inst, Barcelona, Spain
Green Published, Hybrid Gold
|